Bonjour, new guests from small-town India
Puneet Dhawan of Accor is brimming with ideas on ways to revive the hospitality sector
It’s taken 15 years, but evidence is available now that the polypill saves lives, says Denis Xavier at St John’s Medical College and Research Institute, on findings from an international study that has a large India imprint in terms of participation and benefit for heart patients.
“Heart attacks, strokes and other cardiovascular incidents can be cut by 20-40 per cent through use of a polypill, which combines three blood pressure and one lipid-lowering medications, taken alone or with aspirin,” the study said.
This is the third study on this polypill, says Xavier, professor at St John’s in Bengaluru and head of the division of clinical research. Describing it as “the final frontier”, he says the study provided evidence that the combination medication, that has been around for about 10 years, saved lives.
ALSO READ: Covid-19 patients with immune dysfunctions, congenital heart disease at greater risk of death: Study
Although the formulation of different polypills may vary, the polypill used in this study included 40 mg simvastatin; 100 mg of atenolol; 25mg of hydrochlorothiazide, and 10 mg of ramipril. It can be combined with 75 mg of aspirin a day, a note on the study said.
Xavier hoped the study would help expand its use by reducing the pill-burden (number of pills taken by a person) from five to one, making it easier for people to stick to their treatment regimen. And this, in turn, benefited people prone to heart diseases, especially in India where the risk was higher than Europe or America, he added.
The combination-drug harks back to the time of pharma-industry doyens like Anji Reddy, founder of Dr Reddy’s Laboratories and IA Modi, founder of Cadila Pharma, who were keen on the product due to its “benefit to society”, recalls Xavier.
The study involved over 5,700 patients across 89 centres. India contributed almost half the number, with 2,700 patients across 39 centres, Xavier told BusinessLine. The medication was provided by Cadila Pharma. The international study was done by St John’s in collaboration with Canada’s Population Health Research Institute (PHRI) of McMaster University and Hamilton Health Sciences.With about taken eight years to complete the study globally, participants took the medication for an average of 4.5 years. The study has been published in the New England Journal of Medicine.
“A polypill is not only effective, it is likely to be cost effective since it is based on using commonly used generic drugs,” observed Prem Pais, co-principal investigator of the study and professor at St. John’s.
Pointing out that the adverse events were minimal, Xavier said that most people could take the medication in the fixed-dose combination. Some cardiac doctors had pointed out that a fixed dose made it inconvenient for doctors to vary the dosage for different patients.
Salim Yusuf, co-principal investigator for the study and professor of medicine at McMaster University in Canada, said, “This is the start of a transformational approach to preventing heart disease, we could save millions of people from experiencing serious heart disease or stroke each year with effective use of the polypill and aspirin.”
Balram Bhargava, Director General, Indian Council of Medical Research observed that the polypill was worth considering for widespread use. “Costs can be further reduced for our people if and when it enters our national programs.”
The study was supported by agencies including Wellcome Trust UK, Canadian Institutes of Health Research, Heart and Stroke Foundation of Canada and Hamilton Health Sciences Research Institute, Canada, the note said.
ALSO READ: Aspirin lowers risk of Covid-19 complications: Study
Puneet Dhawan of Accor is brimming with ideas on ways to revive the hospitality sector
Citroen’s first vehicle sports a novel design and European interiors. It is also meant to be as comfortable as ...
The pandemic is only the tip of the iceberg that the country’s cash-poor airlines — both regional and national ...
The government is yet to specify the framework of its recently announced old vehicle scrappage policy
With initial public offerings galore, we give you a cheat sheet to score some good grades
Biggest risk in selling funds in a rising scenario is exiting early and missing out on further gains
Go for a standard vector-borne diseases policy if you don’t have a regular health plan
No credit risk is an attraction, but note the nuances
With the public looking beyond mainstream media for reports from the ground, independent digital platforms are ...
While Supreme Court has cleared the way for women seeking longer tenures and senior roles in the Indian Army, ...
Mughal Gardens in the Capital open to visitors — albeit with Covid-19 protocol — for the annual Udyanotsav
Salty, buttery, cheese coated or with maple syrup and bacon — popcorn is lending its adaptable self to gourmet ...
Its name is the starting point of a brand’s journey and can make a big difference in the success sweepstakes
Sober spirits are the in thing
A peek into where ad spends went last year and where they are headed tomorrow
Can Swiggy Instamart disrupt the ecommerce groceries space, currently ruled by the Amazons and Big Baskets? ...
Three years after its inception, compliance with GST procedures remains a headache for exporters, job workers ...
Corporate social responsibility (CSR) initiatives of companies are altering the prospects for wooden toys of ...
Aequs Aerospace to create space for large-scale manufacture of toys at Koppal
And it has every reason to smile. Covid-19 has triggered a consumer shift towards branded products as ...
Please Email the Editor